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Abstract  
The surge in genetic and genomic investigations over the past five years resulted in 
many discoveries of causative variants relevant to disease pathophysiology. 
Although phospholipase C enzymes have long been recognized as important 
components in intracellular signal transmission, it is only recently that this approach 
highlighted their role in disease development through gain-of-function mutations. In 
this review, we describe these new findings, linking the phospholipase Cγ family to 
immune disorders and cancer, and illustrate further efforts to elucidate the molecular 
mechanisms that underpin their dysfunction.  
 
 
Phospholipase C (PLC) enzymes back under the spotlight 
PLC enzymes form key elements in signal transmission networks, linking almost all 
types of cell-surface receptors to downstream components that are involved in the 
regulation of a variety of cellular functions [1-5]. In mammals, six families of PLCs 
(PLCβ, γ, δ, ε, η and ζ) fulfill this role, each characterized by a distinct set of 
regulatory links. The PLCγ family (PLCγ1 and PLCγ2, encoded by the genes PLCG1 
and PLCG2, respectively) transmits signals triggered by many growth factors, 
antigens, and other extracellular stimuli to regulate both essential functions in 
multiple cell types, and specific responses of particular specialized cells from the 
immune system (Box 1). Ubiquitously expressed PLCγ1 is mainly activated 
downstream of growth factor stimulation, including stimulation by platelet derived 
growth factor (PDGF), vascular endothelial growth factor (VEGF), epidermal growth 
factor (EGF), and fibroblast growth factor (FGF). PLCγ2, being predominantly 
expressed in haematopoietic cells, is activated by immune cell receptors such as B-
cell and Fc receptors. The exception is T-cell receptor activation, which is linked to 
PLCγ1, not PLCγ2. PLCγ enzymes are mainly activated through tyrosine 
phosphorylation by receptor and non-receptor kinases. As in all other PLC families, 
the main signaling output is generation of the second messengers inositol 1,4,5-
trisphosphate (IP3, or InsP3) and diacylglycerol (DAG), from phosphatidylinositol 4,5-
bisphosphate (PIP2, or PtdIns(4,5)P2). The released IP3 binds to IP3 receptors on the 
endoplasmic reticulum resulting in Ca2+ release into the cytoplasm. DAG remains in 
the membrane and activates some isozymes of protein kinase C (PKC), other 
kinases and GTPase regulating proteins. PIP2 itself has functions through 
interactions with proteins such as ion channels and components of the actin-
cytoskeleton [6]; therefore, PLC enzymes could also impact these processes by 
changing local concentrations of PIP2.  
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Different aspects of PLC-mediated signalling have been covered in a number of 
excellent reviews that focus, for example, on the catalytic mechanism [7], regulatory 
interactions and physiological roles of PLC families [1-5] or on structural and 
mechanistic aspects of regulation [8-10]. In this review, we highlight recent 
experimental evidence related to the dysfunction of PLCγ enzymes and links to 
disease, based on genetic and genomic analysis of animal models and patients; we 
further discuss the molecular mechanisms that underpin dysfunction. These recent 
findings, supporting a connection between PLCγ variants harbouring key, gain-of-
function mutations and disease development, provide a new perspective for the role 
of PLC enzymes in various disorders and underscore their importance as therapeutic 
targets.  
 
 
Mutations in PLCγ  enzymes and disease development 
The discovery of putative disease-causing mutations in PLCγ enzymes (Tables 1 and 
2) reflects a surge in genetic and genomic investigations that has been facilitated by 
the development of massively parallel, high-throughput, next-generation sequencing 
[11, 12]. Germline mutations in PLCγ have emerged as the cause of certain immune 
disorders, and somatic mutations have been identified as drivers of some types of 
cancer.  
 
PLCγ mutations in immune diseases 
The first link between PLCγ2 and immune diseases was established in the context of 
a large-scale ENU (N-ethyl-N-nitrosourea) mutagenesis screen, in which gain-of-
function mutations were identified (Table 1). Two mouse strains with limb defects, 
abnormal limb 5 and 14 (Ali5 and Ali14) were found to harbour single amino acid 
replacements in PLCγ2, leading to severe autoinflammatory disease [13-15]. 
 
More recently, genetic analyses revealed the role of PLCγ2 in dominantly inherited 
human immune disorders (Table 1). Germline deletion mutations were identified in 
three families with multiple cases of complex immune disease, designated as PLAID 
(PLCG2-associated antibody deficiency and immune dysregulation) [16]. These 
mutations, resulting in constitutive PLC activation, diminished downstream signalling. 
Both Ca2+ flux and extracellular signal-regulated kinase (ERK) phosphorylation were 
reduced in B cells. NK cells showed reduced Ca2+ flux and reduced degranulation, 
while Ca2+ flux in T-cells was normal. These downstream effects were unexpected 
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given the gain of enzymatic function; however, they might be the result of local PIP2 
depletion or of feedback inhibition leading to down-regulation of distal signalling 
pathways. This complex downstream signalling output is also reflected by the 
presence of both autoimmune disorder and immune dysfunctions in patients with 
these mutations. Moreover, reduced temperatures alter the signalling downstream of 
PLCγ2 at the cellular level in these patients, triggering degranulation of mast cells; 
this results in the condition known as cold-induced urticaria. 
 
Another genetic study of an inherited immune disease identified S707Y substitution 
in PLCγ2; the associated disease was designated as APLAID (autoinflammatory 
PLAID) [17]. Discovery of the causal mutation was not amenable to linkage analysis 
and required whole exome sequencing of the germline of individuals from the 
affected family (Table 1). APLAID patients do not suffer from cold-induced urticaria, 
and autoinflammatory disease is more pronounced than immune dysfunction. In 
contrast to cells with PLCγ2 deletions, the S707Y substitution not only leads to a gain 
of enzymatic function but also to increased downstream signalling, specifically Ca2+ 
flux and ERK phosphorylation in B cells [17]. Possibly, the smaller increase in PLCγ2 
activity, relative to the PLAID-causing deletion, that is caused by the point mutation 
might not be sufficient to trigger a negative feedback mechanism. One common 
manifestation for both disorders is the absence of class-switched memory B-cells; 
however, this is probably the result of distinct downstream signalling effects. 
 
PLCγ mutations in cancer 
PLCγ enzymes contribute to some oncogenic signalling pathways through signal 
transduction downstream of receptor and non-receptor tyrosine kinases. It is 
therefore conceivable that aberrant PLCγ activity may contribute to tumour 
development. Initial studies indicated that higher expression levels of PLCγ1 
occurred in a variety of malignancies such as breast or colon cancer [18, 19]. More 
recently, acquired (somatic), driver mutations in the PLCG genes have been 
identified by massively parallel sequencing in angiosarcoma, cutaneous T-cell 
lymphoma (CTCL), and in chronic lymphocytic leukaemia (CLL) (Table 2). Within 
each tumour type, recurrent missense mutations of a specific residue were found, 
which is the hallmark of activating driver mutations [20-22]. Thus, PLCG1/2 
mutations are likely to activate the respective enzymes, although the distal 
downstream functional consequences of specific mutations probably vary. Initial data 
also suggest that calcium responses and proximal signalling (such as 
phosphorylation of a subset of intracellular targets) could also be commonly up-
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regulated [21, 22]. In angiosarcoma, a vascular tumour with endothelial 
differentiation, activating PLCG1 mutations are likely to result in overactive 
angiogenesis growth factor signaling. In CTCL and CLL activation of PLCγ enzymes 
would be predicted to enhance T-cell receptor and B-cell receptor signaling, 
respectively, thereby promoting tumour growth. An important clinical implication of 
PLCG1/2 mutations is that they may represent a resistance mechanism to inhibitors 
of tyrosine kinases. This is exemplified by the case of PLCG2 mutations in CLL, 
which were found in patients who developed resistance to the tyrosine kinase 
inhibitor, ibrutinib [22]. An interesting detail of the mutational data on PLCγ1 in human 
tumours is that the mutations may show tumour type specificity. Although the overall 
number of cases that have been studied to date are low, for PLCγ1 it appears that 
R707 is mutated in angiosarcoma whereas S345 is mutated in CTLC [20, 21]. If 
confirmed in larger studies, such tumour type specificity would indicate that despite 
both occurring in the same gene and being activating, these mutations are non-
interchangeable and modulate function of PLCγ1 enzyme in different ways.  Ongoing 
efforts to characterize cancer genomes will define the extent to which PLCG1/2 
mutations contribute to different types of human cancer, beyond angiosarcoma, 
CTCL, and CLL. At the same time, mechanistic studies into PLCγ are required to 
elucidate changes in enzyme function in the context of specific diseases. 
 
Structural and mechanistic aspects of PLCγ  function and mechanisms of 
deregulation  
A large number of studies related to regulatory interactions of PLCγ enzymes 
identified tyrosine phosphorylation of PLCγ as the major mechanism of activation. 
Some other, phosphorylation-independent mechanisms, such as activation of PLCγ2 
by Rac, were also revealed (Box 1). However, it was only recently that sufficient 
structural information became available that would allow understanding of 
deregulation at the molecular level (Figures 1 and 2).  
 
Structural basis of auto-inhibition and activation of PLCγ proteins 
Understanding the molecular mechanisms underlying auto-inhibition and activation of 
PLCγ isoforms has been an intense area of research for over 20 years. Early work, 
focussing on the differences between PLCγ, δ and β regulation, determined that 
PLCγ signalling lay downstream of receptor tyrosine kinases (RTKs) [23]. 
Consequently, recruitment and subsequent phosphorylation of PLCγ by RTKs was 
shown to be crucial for activation. Later reports provided evidence that 
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phosphorylation on tyrosine 783 (Y783), located within the region specific to PLCγ 
enzymes (γ specific array or γSA; Figure 1), was both required and sufficient for 
PLCγ activation. Further, Y783 phosphorylation created an intramolecular binding site 
for the C-terminal src-homology 2 (cSH2) domain [24]. The main role of the N-
terminal src-homology 2 (nSH2) domain is to engage RTK. In the specific case of the 
FGF receptor (FGFR), the nSH2 binds to the receptor through canonical 
phosphotyrosine pY and through secondary sites [25] leading to an exquisitely 
specific interaction. As well as playing a crucial role in the activation of PLCγ, the 
cSH2 domain was shown to be critical for maintaining auto-inhibition [26-28]. In 
addition, the “split” pleckstrin homology (spPH) domain has been reported to 
contribute to maintenance of PLCγ in the auto-inhibited state in the absence of 
phosphorylation [26, 28]. 
 
Despite these advances, the precise molecular basis of auto-inhibition and activation 
and importantly the amino acid residues crucial for these phenomena were unknown 
due to the lack of critical structural information, in particular related to the full-length 
PLCγ molecule and unique γSA (depicted in Figure 1A, top panel). Generating an X-
ray crystallographic structure proved challenging due to the inherent flexibility in 
various regions of the protein. Nevertheless, other techniques are available that have 
provided insight into the structural arrangements of the γSA and its interactions with 
the core. For instance, a combination of nuclear magnetic resonance (NMR), small 
angle X-ray scattering (SAXS), crystallography (of fragments of the protein), 
isothermal titration calorimetry (ITC) and modelling were utilised to study PLCγ1 [29]. 
Previous studies that highlighted the sole importance of Y783 in PLCγ1 activation 
were confirmed. Furthermore, NMR spectroscopy showed that the spPH, nSH2 and 
src-homology three (SH3) domains made few interactions with each other in the γSA.  
By contrast, comparing the cSH2 spectrum with the γSA spectrum suggested that 
there are dynamic interactions between cSH2 and the other domains and linkers 
within γSA. Upon further analysis of tandem γSA fragments (cSH2-spPH), compared 
to isolated domains, it was clear that cSH2 and spPH have a transient interaction.  
 
SAXS, a method that provides low-resolution structures of proteins in solution, was 
performed on the γSA, a number of tandem domains within the γSA and various 
tagged and complexed constructs [29]. Taking into account the SAXS and NMR 
data, a model was generated representing a possible average structural 
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arrangement of the γSA, in which the spPH and cSH2 occupy the central lobe with 
nSH2 and SH3 peripheral to them (Figure 1A, bottom panel). 
 
PLCγ activation through the interaction between cSH2 and pY783 has been known for 
some time, having been established through various lines of evidence. However, the 
crystal structure of phosphorylated tandem nSH2-cSH2, showing that residues 781 
to 790 bound in cis to the canonical cSH2 pY peptide binding pocket, was obtained 
only recently [29]. The crucial pY783 interacts with three arginine residues, R675, R694 
and R696. Also, V784, A786 and P788 make van der Waals contacts with the cSH2 
surface and bury approximately 620Å2 of solvent accessible surface. A second 
crystal structure was later reported of the isolated cSH2 domain bound in trans to a 
PLCγ1 derived phosphopeptide [30]. Interestingly, ITC experiments performed with 
the apo nSH2-cSH2, the phosphorylated nSH2-cSH2 and FGFR1pY766 
(phosphorylation at tyrosine 766 creates a binding site for PLCγ) showed that the 
affinity of the nSH2 domain for FGFR1 decreased upon engagement of the pY783 
linker in the cSH2 binding site [29]. The decreased affinity of phosphorylated γSA and 
full length PLCγ for FGFR1 was also reported using a pull-down assay. The 
intriguing possibility that phosphorylated PLCγ has a lower affinity for RTK than 
unphosphorylated PLCγ suggests that many PLCγ molecules can be phosphorylated 
by a single RTK. This would lead to greater signal amplitude than if the PLCγ 
remained engaged with the RTK. 
 
Confirmation that the cSH2 is the domain in γSA directly involved in auto-inhibition 
came from NMR titration experiments [29]. The PLC-core from PLCγ was added 
independently into 15N labelled domains of nSH2, cSH2 and spPH. An interaction 
could be measured only between the core and the cSH2 domain and this could be 
reversed through subsequent addition of the pY783 linker. Importantly, this approach 
also revealed which surface of the cSH2 domain is in contact with the catalytic core 
of PLCγ and showed that this surface overlaps with the binding surface of the pY783 
linker.  ITC with mutated cSH2 and/or core polypeptides confirmed that the following 
residues are important at the cSH2/core interface: R748, R753, N728, S729 and 
D1019. Introducing substitutions in these residues into full length PLCγ and assaying 
for PLC activity in cells also showed that disrupting the cSH2/core interface imparted 
increased basal activity and increased EGF stimulated activity compared to wild type 
protein [29]. Therefore, a clearer picture of the molecular basis of auto-inhibition and 
activation emerges from these data (Figure 1B). In the basal state, the low PLCγ 
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catalytic activity is maintained through a specific interaction between the cSH2 
domain and residues surrounding the active site. Phosphorylation at Y783 creates a 
binding site for the cSH2 domain that is of greater affinity than its binding site at the 
core. With the cSH2 occlusion removed from the active site the protein can now 
access its substrate in the membrane. 
 
 
Structural basis of dysfunction  
The structural basis of auto-inhibition and activation provides a useful framework for 
interpretation of the effects of various mutations and brings together observations 
from mouse models and human diseases, including immune disorders and cancer 
(Figure 2). Given that the cSH2 domain was found to form an autoinhibitory interface 
with the catalytic domain, it is not surprising that the partial or complete deletion of 
this domain, as it is the case in PLAID patients, leads to a constitutively active PLCγ2 
enzyme (Figure 2). The mechanism of auto-inhibition also explains some of the more 
subtle disease-associated mutations; for instance the S707Y substitution found in 
APLAID patients, disturbs the autoinhibitory interface between cSH2 and the catalytic 
domain, which was confirmed by NMR and ITC studies [29]. The effect of this 
mutation on the enzymatic activity is less pronounced than for cSH2 deletions. This 
S707Y mutation is also an example of a point mutation that was found in both 
immune disease and cancer; recently, some patients with ibrutinib-resistant CLL 
were found to harbour this mutation, either in isolation or in combination with other 
PLCγ2 mutations and/or a C481S mutation in Bruton's tyrosine kinase, the target of 
ibrutinib [22]. Our understanding of the functional effect of these mutations can also 
be transferred to a recently discovered PLCγ1 point mutation that results in the 
substitution R707Q in angiosarcoma. R707Q (not to be confused with S707Y in 
PLCγ2) is located within the beta-sheet of the cSH2 domain. A destabilization of 
cSH2 structure, leading to a gain of enzymatic function by a similar mechanism, 
seems likely [20]. The PLCγ2 substitution R665W, found in ibrutinib-resistant CLL 
samples, is also located in the cSH2 domain [22]. Residue R665 in PLCγ2  
(equivalent to PLCγ1 R687) is spatially close to PLCγ1 residue R707 mutated in 
angiosarcoma. However, it is more surface-exposed than the latter; therefore, it is 
not yet clear how its activating effect occurs. 
 
Other mutations directly affecting PLCγ autoinhibition affect the ridge region of the 
catalytic domain (Figure 2). For instance, mice with the ALI5 phenotype harbour the 
substitution D993L in PLCγ2, which leads to only a small increase in basal PLCγ 
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activity; however, the activity following stimulation is greatly enhanced compared to 
the wild type [13, 15]. ITC, NMR and surface plasmon resonance experiments 
suggest that the reason for the higher activity in cells is the disruption of the 
autoinhibitory interface between the catalytic domain and the cSH2 domain, 
combined with enhanced membrane recruitment [15, 29]. The PLCγ1 S345F 
substitution, found in CTCL samples, is also located in the ridge region of the 
catalytic domain. Furthermore, based on a previous structural study, it was predicted 
that the specific region around this residue forms the autoinhibitory interface between 
cSH2 and the catalytic domain [29]. It can be inferred that the PLCγ1 S345F 
substitution is likely to disrupt the autoinhibitory interface in a similar fashion to the 
immune disease-causing PLCγ2 D993L substitution in ALI5 mice. 
 
The Y495C substitution in PLCγ2, which is found in mice with the ALI14 phenotype, 
leads to symptoms similar to those observed for ALI5 mice [14, 15]. Y495 is located 
in the beta-sheet in the spPH domain, which only in PLCγ2 binds Rac. In cells 
expressing Y495C variant, basal and Rac or EGFR-stimulated PLCγ2 activity was 
found to be increased. This observation, in combination with NMR and ITC studies, 
illustrates that this substitution does not change the interaction between spPH and 
Rac, but rather destabilizes the γSA and thereby contributes to overcome auto-
inhibition and facilitate activation [31]. It is possible that other cSH2-spPH interaction 
contacts could have a role in this context [29]. The recently discovered PLCγ1 S520F 
substitution in CTCL and to some extent also the PLCγ2 L845F substitution in 
ibrutinib-resistant CLL are spatially close to the ALI14 substitution, Y495C (Figure 2). 
This suggests that these cancer-associated substitutions could both be activating 
PLCγ1 and PLCγ2 by destabilizing γSA, and consequently relieving auto-inhibition, 
as was found to be the case for the ALI14 substitution.  
 
Deletions and single amino acid substitutions in PLCγ1 and PLCγ2 identified so far 
directly affect enzyme activity as a common functional outcome, further supporting 
genetic evidence for the link between these mutations and disease development. 
Based on these findings, PLCγ enzymes should be further considered as a potential 
therapeutic target.      
 
 
Pharmacological inhibitors of PLC activity  
Selective small molecules or other selective probes are critical in elucidating 
physiological and aberrant functions of specific proteins in cells and whole 
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organisms. Furthermore, such compounds serve as candidates for drug 
development. Specific pharmacological inhibitors and promising drug compounds 
have now been developed for many signalling components of “core processes” 
operating in signal transmission within cellular networks. PLC enzymes, however, 
notably lack not only potential drug molecules but, it appears, there is not even a 
reliable, direct small molecule inhibitor. Based on structural insights and a detailed 
understanding of the catalytic mechanism of PIP2 hydrolysis [7], PLC proteins are not 
intrinsically intractable. The main limitations in inhibitor development have been 
related to a lack of suitable high-throughput screening, difficulties of generating 
chemical probes based on the PIP2 substrate and insufficient evidence linking 
changes in PLC function with disease development. As discussed further in Box 2, all 
these problems are now being addressed.  
 
Recent advances in studies of PLC enzyme, however, also highlighted some new 
important points that should be considered in future developments of PLC inhibitors.  
The new findings support diverse, and sometime opposing roles of different PLC 
isoforms, in particular in cancer [20-22, 32-37], and indicate that the generation of 
isozyme-specific inhibitors is highly desirable. Nevertheless, recent studies of the 
gain-of-function mutations that affect auto-inhibitory surfaces (Figure 2) would imply 
that active site of these variants can be more exposed and accessible, suggests the 
possibility that more general PLC inhibitors could also be effective. 
 
 
 
Concluding remarks 
The emergence of pathogenic PLCγ1 and PLCγ2 mutations in human cancer and 
autoimmune diseases may herald the discovery of further examples of human 
disease that is driven by aberrant PLCγ1 or PLCγ2 function. Despite the high 
structural and mechanistic overlap, PLCγ1 and PLCγ2 are relevant in very different 
medical conditions. All mutated sites linked to human diseases are conserved 
between PLCγ1 und PLCγ2. Furthermore, all identified mutations appear to be gain-
of-function by destabilising the regulatory γSA and/or by disrupting the autoinhibitory 
interface between γSA and the catalytic domain. Studies of relevant murine models 
and patients, together with structural insights, will help to understand new mutations 
occurring in very different contexts. Further research, covering molecular 
mechanisms, animal models of disease and specific and potent PLC inhibitors, will 
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be needed as the next step towards full elucidation of the role of PLCγ enzymes in 
various disorders.  
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FIGURES  
Figure 1. Structural insights in PLCγ regulation. 
A) Liner (top) and 3-D representation (bottom) of domains that comprise PLCγ 
isoforms. The protein is organized into two regions: the PLC-core, shared by PLC 
families, and the array of domains specific for PLCγ family (γSA). Each domain within 
the PLC-core [an N-terminal pleckstrin homology (PH) domain, EF-hands, 
triosephosphate isomerase (TIM)-barrel like fold and a C2 domain] and γSA [“split” 
PH domain (spPH), two src-homology two (SH2) domains (nSH2 and cSH2) and one 
src-homology three (SH3) domain] is represented in a different colour. In linear 
representation (top), to emphasize two regions in PLCγ family, the PLC-core and γSA 
domains are shown along separate axis. Proposed structural arrangements within 
these two regions are shown as surface and ribbon representations (bottom panels). 
Bottom left, an SAXS- and NMR-based model of a likely dynamically averaged 
conformation of the γSA in the non-phosphorylated state. Each domain (shown in a 
different colour as in top panel) is represented as a surface. The cSH2 domain is 
also illustrated as a ribbon representation and the region shown to be involved in 
auto-inhibition is indicated. The interaction interfaces of Rac with the spPH domain of 
PLCγ2 and of tyrosine kinases with the nSH2 are indicated. Bottom right, a model of 
the core domains (excluding the PH domain, based on PDB: 2ZKM) is shown as 
surface structures with the TIM-like barrel also represented by a ribbon. The position 
of IP3 – representing the headgroup of the PIP2 substrate- is modelled into the TIM-
like barrel (based on crystal structure of another isozyme; PDB: 1DJX), showing the 
site of catalysis. The surface involved in autoinhibition is also indicated.  
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B) Molecular basis of PLCγ autoinhibition and activation. The autoinhibited (inactive, 
left panel) form of the PLCγ molecule is represented using the same domain colours 
as in the above structural representations. The TIM-like barrel and cSH2 domains 
are shown juxtaposed in the likely orientation that confers autoinhibition on the 
unphosphorylated molecule. Subsequent phosphorylation by tyrosine kinases on Y783 
leads to interruption of the autoinhibitory interface through binding of the cSH2-SH3 
linker to the canonical binding site on the cSH2 surface (right panel). This event 
leads to a change in the conformation of the γSA with respect to the PLC-core that 
reveals access to the active site so that catalysis can proceed. 
 
 
Figure 2. Molecular mechanisms of PLCγ deregulation. 
A) Locations of disease-relevant amino acid substitutions identified in PLCγ1 or 
PLCγ2 are indicated by red arrows. In addition to point mutations, deletions affecting 
the cSH2 domain have also been described. All mutations are activating. Surface 
areas of the TIM-like barrel (catalytic domain) and cSH2 domain form the 
autoinhibitory interface (marked by a red line).  
 
B) Mutations in the spPH domain. Three amino acid substitutions, Y495C and L845F 
in PLCγ2 and S520F in PLCγ1, are listed; for amino acid substitutions in PLCγ2 the 
corresponding wild type residues in PLCγ1 are shown below in brackets. All residues 
affected by mutations are indicated in structural representation using numbering 
corresponding to PLCγ1 sequence. All mutations are located at (or close to) the 
cSH2-spPH interaction interface, distinct from the interface between spPH and Rac. 
They are likely to destabilize the γSA region of the protein. The structural model has 
been created from a combination of spH structures (PDB: 2FJL and 2W2X) and the 
γSA model by aligning the spPH domains of these models. 
 
C) Mutations in the cSH2 domain. Two amino acid substitutions in PLCγ2 (E665W 
and S707Y) and one in PLCγ1 (R707Q) are listed; for amino acid substitutions in 
PLCγ2 the corresponding wild type residues in PLCγ1 are shown below in brackets. 
All residues affected by mutations are indicated in structural representation (PDB: 
4FBN) using numbering corresponding to PLCγ1 sequence. The S707Y substitution 
activates by disrupting the autoinhibitory interface with the catalytic domain. R707Q 
is not located at the interface, but within the beta sheet. This substitution might lead 
to disruption of the structure and thereby also release autoinhibition. E665W is 
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spatially close to R707Q and part of the protein surface. Other residues, considered 
to be a central part of the autoinhibitory interface between the cSH2 and catalytic 
domain, are also shown.  
 
D) Mutations in the catalytic domain. Two amino acid substitutions (D993G in PLCγ2 
and S345F in PLCγ1) are listed; for the amino acid substitution in PLCγ2 the 
corresponding wild type residues in PLCγ1 is shown below in brackets. Both residues 
affected by mutations are indicated in structural representation using numbering 
corresponding to PLCγ1 sequence. The substituted residues are located at the 
proposed autoinhibitory interface. For D993G, it was demonstrated that this interface 
is disrupted as a consequence of the mutation; therefore both mutations are likely to 
activate PLCγ by disrupting autoinhibition. Following activation, they may also 
facilitate interaction with the cellular membrane.  
 
 
BOXES 
Box 1. Domain organization of PLCγ enzymes and their roles in signal 
transduction. 
PLCγ1 and PLCγ2 have the same domain organisation and share high sequence 
similarity across all domains [4, 5, 8] (Figure IA). They incorporate a core set of 
domains (PLC-core): an N-terminal pleckstrin homology (PH) domain, EF-hands, 
triosephosphate isomerase (TIM)-barrel like fold and a C2 domain. Uniquely for 
PLCγ, the linker between the two–halves (X and Y boxes) of the TIM-barrel is highly 
structured and referred to as the γ specific array (γSA).  γSA consists of a “split” PH 
domain (spPH), two src-homology two (SH2) domains (nSH2 and cSH2) and one 
src-homology three (SH3) domain. While the PLC-core contains TIM-barrel with the 
enzymatic function, the γSA is largely involved in interaction with regulatory proteins.  
 
PLCγ1 and PLCγ2 are activated downstream of receptor (RTK) and non-receptor 
tyrosine kinases [38, 39]. Stimulation via RTKs is best documented for PLCγ1 
(Figure 1B, left). Action of non-receptor tyrosine kinases has been best defined in the 
context of activation of immune cell (T-cell, B-cell and Fc) receptors associated with 
multi-protein complexes. Most immune cell receptors activate PLCγ2; the regulatory 
interactions defined in B-cells are shown in Figure 1B, right. More recently it has 
been discovered that PLCγ2 is also activated by the small GTPase Rac [40, 41].  
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Figure I. Similarity between PLCγ enzymes and regulatory links in different 
physiological settings  
A) For each indicated domain shared by PLCγ1 and PLCγ2 the similarity is shown as 
a percentage. Sequence similarity was calculated based on alignment (using 
MUSCLE, EMBL-EBI tool). 
B) Different regulatory interactions of PLCγ downstream of receptor tyrosine kinases 
(RTKs) and immune cell receptors. 
Left panel: Engagement of growth factor (GF) by RTKs creates activated receptors 
(pRTKs). Phosphorylated tyrosines on pRTKs become binding sites for SH2 domain-
containing proteins such as PLCγ1 that are recruited and subsequently 
phosphorylated by the kinase. 
Right panel: Antigen engagement of the B-cell receptor (BCR) leads to 
phosphorylation by the Lyn non-receptor tyrosine kinase within and outside specific 
(ITAM) motifs. This is followed by recruitment of adaptor molecules  (BLNK) and 
further non-receptor tyrosine kinases (Syk). Phosphorylated BLNK acts as a scaffold 
for PLCγ2 where Syk can then phosphorylate and activate the phospholipase. 
Furthermore, Btk is recruited to the membrane environment by parallel pathways and 
can also phosphorylate PLCγ2. Finally, activated Rac can bind and stimulate PLCγ2 
by a phosphorylation independent mechanism (dotted arrow). 
 
Box 2. Developments of pharmacological inhibitors that target PLC enzymes. 
Historically, the first attempts to develop pharmacological inhibitors against PLC were 
focused on the development of PIP2-based chemical probes that could be used as a 
substrate in screens and as lead compounds. Despite the initial difficulties, some 
promising, fluorogenic substrate analogues were reported [42-45]. Paralleling this 
work, compounds that were structurally unrelated to PIP2 were identified as potential 
PLC inhibitors. Among those, aminosteroid U73122 has been the most frequently 
used. However, it was difficult to directly and strictly link the effects of such inhibitors 
to PLC inhibition for functional readouts in cells. Furthermore, a number of reports on 
U73122 suggested it had other targets, including calcium pumps and unrelated 
enzymes regulating lipid metabolism [46-51]. It has also been shown that treatment 
of purified PLC isoforms with U73122 in vitro had surprisingly diverse effects on 
activity, including increased activity of PLCγ [52]. These observations highlighted the 
need to reevaluate these early inhibitors and generate new, specific compounds 
against PLC isoforms.  
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Renewed efforts to target PLC enzymes are underway. Several novel inhibitors were 
identified using virtual high-throughput screening based on the 3D-structure of the 
PLC active site [53]. Significantly, ongoing efforts to develop a second generation of 
PIP2-based chemical probes are also promising [54-56]. In particular, soluble, 
fluorogenic analogs will continue to greatly facilitate high-throughput screening to 
identify highly specific and more potent PLC inhibitors [56]. These PIP2 analogues 
could also guide the generation of inhibitory compounds that bind to the conserved 
PLC active site. 
 
As documented in this review, significant progress has been made in providing 
supporting data for the involvement of PLCγ enzymes in disease development where 
in many cases current treatments remain ineffective. This to a considerable degree 
addresses one of the previously raised issues of insufficient evidence linking 
changes in PLC function with diseases in need of new treatments. 
 
 	  	  
 
 
Table	  1.	  PLCγ	  mutations	  related	  to	  immune	  disease	  
Protein	  
names	  
Mutation	   Domain	   Occurrence	  of	  
mutation	  
Subjects	   Clinical	  manifestations	   Activity	  a:	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
IP3,	  Ca2+,	  
distal	  a	  
Anti-­‐
bodies	  
T	  and	  B	  
cells	  
Ref.	  
PLCγ2	   D993G	  	   TIM-­‐barrel	   murine	  mutation	  from	  ENU	  mutagenesis	  ("ALI5")	  
mouse	  line	   autoinflammation:	  inflammatory	  skin	  lesions	  (with	  inflammatory	  infiltrate),	  arthritis,	  keratitis,	  glomerulonephritis	  (ICECPGN),	  autoantibodies;	  other:	  growth	  retardation.	  	  
	  	  ↑,	  ↑,	  o	  	   IgM↑,	  some	  IgG↑	   T	  cells↑,	  	  B	  cells↓	   [11,13]	  
PLCγ2	   Y495C	  	   spPH	   murine	  mutation	  from	  ENU	  mutagenesis	  ("ALI14")	  
mouse	  line	   autoinflammation:	  inflammatory	  skin	  lesions	  (with	  inflammatory	  infiltrate),	  arthritis;	  other:	  metabolic	  defects,	  reduced	  male	  fertility.	  
	  	  ↑,	  ↑,	  o	  	   IgM↑,	  some	  IgG↑	   T	  cells↑,	  	  B	  cells↓	   [12,13]	  
PLCγ2	   Δ(646-­‐685)	  	  
cSH2	   inherited	  mutation	  	   27	  patients	  (3	  families)	   PLAID.	  autoinflammation:	  cold-­‐induced	  urticaria,	  granulomatous	  skin	  disease,	  autoimmune	  disease,	  allergic	  disease;	  autoantibodies;	  
immune	  deficiency:	  	  recurrent	  sinopulmonary	  infection,	  common	  variable	  immunodeficiency.	  	  
	  	  ↑,	  ↑,	  ↓	   IgM↓,	  IgA↓,	  IgE↑	  	  
class-­‐switched	  memory	  B	  cells↓	  	  
[14]	  
PLCγ2	   Δ(686-­‐806)	   cSH2	  /	  SH3	  
PLCγ2	   S707Y	  	   cSH2	   de	  novo	  and	  inherited	  mutation	   2	  patients	  (1	  family)	   APLAID.	  autoinflammation:	  inflammatory	  skin	  lesions	  (with	  inflammatory	  infiltrate),	  arthralgia,	  keratitis,	  enterocolitis,	  	  interstitial	  pneumonia;	  immune	  
deficiency:	  recurrent	  sinopulmonary	  infection,	  cellulitis	  
	  	  ↑,	  ↑,	  ↑	   IgM↓,	  IgA↓	   NK	  T-­‐cells↓,	  class-­‐switched	  memory	  B	  cells↓	  
[15]	  
aActivity	  of	  PLCγ	  variants	  was	  assessed	  either	  in	  cells	  harboring	  the	  mutation	  or	  in	  transfected	  cells;	  accumulation	  of	  IP3	  or	  of	  Ca2+	  were	  used	  as	  a	  direct	  readout	  of	  PLC	  activity	  and	  further	  downstream	  events	  referred	  as	  "distal";	  up	  and	  down	  arrows	  indicate	  increase	  or	  decrease.	  o:	  no	  data	  available.	  
	  
	  
	  
 
Table	  2.	  PLCγ	  mutations	  related	  to	  cancer	  
Protein	  
names	  
Mutation	   Domain	   Occurrence	  of	  mutation	   Activity	  a:	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
IP3,	  Ca2+,	  
distal	  a	  
Co-­‐mutations	   Ref.	  
PLCγ1	   R707Q	   cSH2	   secondary	  angiosarcoma	   	  	  o,	  o,	  o	   PTPRB	   [17]	  PLCγ1	   S345F	   TIM	  barrel	   cutaneous	  T-­‐cell	  lymphoma	   	  	  o,	  o,	  ↑	   	   [18]	  PLCγ1	   S520F	   spPH	   cutaneous	  T-­‐cell	  lymphoma	   	  	  o,	  o,	  ↑	   	   [18]	  PLCγ2	   R665W	   cSH2	   Ibrutinib	  resistance	  in	  CLL	   	  	  o,	  ↑,	  ↑	   	   [19]	  PLCγ2	   L845F	   spPH	   Ibrutinib	  resistance	  in	  CLL	   	  	  o,	  ↑,	  ↑	   R665W,	  S707Y,	  BTK:	  C481S	   [19]	  
aActivity	  of	  PLCγ	  variants	  was	  assessed	  either	  in	  cells	  harboring	  the	  mutation	  or	  in	  transfected	  cells;	  accumulation	  of	  IP3	  or	  of	  Ca2+	  were	  used	  as	  a	  direct	  readout	  of	  PLC	  activity	  and	  further	  downstream	  events	  referred	  as	  "distal";	  up	  and	  down	  arrows	  indicate	  increase	  or	  decrease.	  o:	  no	  data	  available.	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